Announced on | Meeting on |
Jun 25, 2024 | Jun 29, 2024 |
Others | |
May 02, 2024 | May 17, 2024 |
Audited Results & Final Dividend | |
Mar 04, 2024 | Mar 08, 2024 |
Others | |
Jan 19, 2024 | Jan 31, 2024 |
Quarterly Results | |
Oct 25, 2023 | Nov 04, 2023 |
Quarterly Results |
Poly Medicure Share Price
- Open2,049.95
- High2,111.00
- Low2,049.95
- Prev Close2,048.40
- Volume1,23,006
- VWAP(₹)2,078.84
Poly Medicure share price insights
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 17.87% towards employee cost in the year ending 31 Mar, 2024. (Source: Consolidated Financials)Sell Signal: Bears might roar again
Weekly stochastic crossover appeared on week ending Jul 05, 2024. Average price decline of -7.37% within 7 weeks of this signal in last 10 years.Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of 112.46% as compared to Nifty Midcap 100 which gave a return of 98.13%. (as of last trading session)Stock Returns vs BSE Healthcare
Stock generated 112.46% return as compared to BSE Healthcare which gave investors 45.81% return over 3 year time period. (as of last trading session)Poly Medicure Share Price Update
Poly Medicure Ltd. share price moved up by 1.35% from its previous close of Rs 2,048.40. Poly Medicure Ltd. stock last traded price is 2,075.85
Share Price Value Today/Current/Last 2,075.85 Previous Day 2,048.40
Poly Medicure Share Price Returns
1 Day | 1.35% |
1 Month | 16.89% |
3 Months | 32.43% |
1 Year | 79.68% |
3 Years | 110.53% |
5 Years | 1023.6% |
Key Metrics
PE Ratio(x) | 77.14 |
EPS - TTM(₹) | 26.91 |
MCap(₹ Cr.) | 19,922.23 |
MCap Rank | 7 |
PB Ratio(x) | 13.37 |
Div Yield(%) | 0.14 |
Face Value(₹) | 5.00 |
52W High(₹) | 2,111.00 |
52W Low(₹) | 1,075.00 |
MCap/Sales | 11.08 |
Beta(1 Month) | -0.14 |
BV/Share(₹) | 153.18 |
Poly Medicure Share Recommendations
4 Analysts
SellSellHoldBuyStrong
Buy
Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 1 |
Buy | 2 | 2 | 2 | 3 |
Hold | - | - | - | 1 |
Sell | - | - | - | - |
Strong Sell | - | - | - | - |
# Analysts | 4 | 4 | 4 | 5 |
Poly Medicure News & Analysis
NewsTechnical Breakout Stocks: How to trade RVNL, Balkrishna Industries and Poly Medicure on Wednesday
NewsAhead of Market: 10 things that will decide D-Street action on Wednesday
NewsZydus Lifesciences, Poly Medicure among 10 stocks with RSI trending up Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcements
Poly Medicure Financials
Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Total Income 393.05 356.17 351.39 333.94 315.35 Total Income Growth (%) 10.36 1.36 5.22 5.90 5.38 Total Expenses 297.47 264.88 268.22 248.41 238.43 Total Expenses Growth (%) 12.30 -1.25 7.97 4.19 4.57 EBIT 95.58 91.29 83.17 85.53 76.92 EBIT Growth (%) 4.70 9.77 -2.77 11.20 7.95 Profit after Tax (PAT) 68.36 65.02 62.19 62.70 58.81 PAT Growth (%) 5.14 4.55 -0.81 6.61 17.60 EBIT Margin (%) 24.32 25.63 23.67 25.61 24.39 Net Profit Margin (%) 17.39 18.25 17.70 18.77 18.65 Basic EPS (₹) 7.12 6.78 6.48 6.54 6.13 All figures in Rs Cr, unless mentioned otherwise
InsightsEmployee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 17.87% towards employee cost in the year ending 31 Mar, 2024. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 1,858.67 1,577.21 1,376.83 1,223.73 767.32 Total Assets Growth (%) 17.85 14.55 12.51 59.48 17.34 Total Liabilities 388.62 335.58 289.35 258.16 332.50 Total Liabilities Growth (%) 15.80 15.98 12.08 -22.36 21.98 Total Equity 1,470.05 1,241.63 1,087.48 965.57 434.82 Total Equity Growth (%) 18.40 14.17 12.63 122.06 14.02 Current Ratio (x) 2.40 2.75 3.46 4.12 1.61 Total Debt to Equity (x) 0.12 0.12 0.12 0.11 0.39 Contingent Liabilities 0.00 163.99 169.58 99.20 106.94 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 266.08 190.83 123.47 118.73 130.51 Net Cash used in Investing Activities -240.94 -179.02 -85.33 -435.58 -109.46 Net Cash flow from Financing Activities -20.15 -12.51 -35.34 316.95 -20.51 Net Cash Flow 4.99 -0.70 2.80 0.10 0.54 Closing Cash & Cash Equivalent 12.05 7.06 7.76 4.95 4.86 Closing Cash & Cash Equivalent Growth (%) 70.67 -8.96 56.57 2.00 12.50 Total Debt/ CFO (x) 0.64 0.77 1.01 0.86 1.28 All figures in Rs Cr, unless mentioned otherwise
InsightsIncrease in Cash from Investing
Company has used Rs 240.94 cr for investing activities which is an YoY increase of 34.59%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 17.56 14.43 13.47 14.07 22.04 Return on Capital Employed (%) 23.42 19.03 17.13 17.60 24.88 Return on Assets (%) 13.89 11.36 10.64 11.10 12.49 Interest Coverage Ratio (x) 36.90 34.12 58.99 21.76 7.75 Asset Turnover Ratio (x) 0.80 0.73 0.69 64.26 89.56 Price to Earnings (x) 59.17 51.02 62.11 57.80 21.69 Price to Book (x) 10.37 7.36 8.37 8.12 4.78 EV/EBITDA (x) 36.62 30.20 36.69 33.99 12.18 EBITDA Margin (%) 30.30 27.04 27.19 29.59 26.54
Peer Comparison
NAME 1D 1W 1M 3M 1Y 3Y 5Y Poly Medicure Stock Performance 1.35 15.18 30.53 32.19 110.34 112.46 975.01 Nureca Ltd Stock Performance 1.95 6.43 5.20 -12.00 -26.66 -81.17 0.00 All values in %
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of 112.46% as compared to Nifty Midcap 100 which gave a return of 98.13%. (as of last trading session)Stock Returns vs BSE Healthcare
Stock generated 112.46% return as compared to BSE Healthcare which gave investors 45.81% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
MF Ownership as on 31 May 2024
318.18
Amount Invested (in Cr.)
1.33%
% of AUM
-2.72
% Change (MoM basis)
317.04
Amount Invested (in Cr.)
1.49%
% of AUM
0.00
% Change (MoM basis)
Quant Healthcare Direct-G
Equity: Sectoral-Pharma
26.83
Amount Invested (in Cr.)
9.35%
% of AUM
0.00
% Change (MoM basis)
Corporate Actions
Board Meeting
Others
Jun 25, 2024
Final
60%
May 17, 2024
Board Meeting
Audited Results & Final Dividend
May 02, 2024
Announced on Ex-Date Dividend% May 09, 2023 Sep 21, 2023 60% May 24, 2022 Sep 16, 2022 50% May 24, 2021 Sep 16, 2021 50% Feb 18, 2020 Feb 27, 2020 40% May 17, 2024 - 60% Announced on Ex-Date Feb 06, 2017 Mar 24, 2017 Bonus Ratio: 1 share(s) for every 1 shares held May 13, 2013 Jul 09, 2013 Bonus Ratio: 1 share(s) for every 1 shares held Feb 09, 2010 Mar 26, 2010 Bonus Ratio: 1 share(s) for every 1 shares held Announced on Ex-Date Nov 05, 2014 Feb 02, 2015 Split: Old FV10.0| New FV:5.0 No Data Available
Announced on Meeting on Sep 06, 2023 Sep 28, 2023 A.G.M. Sep 10, 2020 Sep 29, 2020 Book closure from 23 Sep, 2020 to 29 Sep, 2020 Aug 30, 2019 Sep 23, 2019 Book closure from 17 Sep, 2019 to 23 Sep, 2019 Feb 28, 2019 Mar 30, 2019 - Sep 04, 2018 Sep 26, 2018 Book closure from 20 Sep, 2018 to 26 Sep, 2018
About
Poly Medicure Ltd., incorporated in the year 1995, is a Small Cap company (having a market cap of Rs 19,922.23 Crore) operating in Hospitals & Allied Services sector.
Poly Medicure Ltd. key Products/Revenue Segments include Medical Equipments & Accessories, Export Incentives, Scrap for the year ending 31-Mar-2023.
For the quarter ended 31-03-2024, the company has reported a Consolidated Total Income of Rs 393.05 Crore, up 10.36 % from last quarter Total Income of Rs 356.17 Crore and up 24.64 % from last year same quarter Total Income of Rs 315.35 Crore. Company has reported net profit after tax of Rs 68.36 Crore in latest quarter.
The company’s top management includes Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra. Company has M C Bhandari & Co. as its auditors. As on 31-03-2024, the company has a total of 9.60 Crore shares outstanding.
About Poly Medicure
Poly Medicure Ltd., incorporated in the year 1995, is a Small Cap company (having a market cap of Rs 19,922.23 Crore) operating in Hospitals & Allied Services sector. Poly Medicure Ltd. key Products/Revenue Segments include Medical Equipments & Accessories, Export Incentives, Scrap for the year ending 31-Mar-2023.For the quarter ended 31-03-2024, the company has reported a Consolidated Total Income of Rs 393.05 Crore, up 10.36 % from last quarter Total Income of Rs 356.17 Crore and up 24.64 % from last year same quarter Total Income of Rs 315.35 Crore. Company has reported net profit after tax of Rs 68.36 Crore in latest quarter.The company’s top management includes Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Devendra Raj Mehta, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Himanshu Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Rishi Baid, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Alessandro Balboni, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mr.Jugal Kishore Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Mrs.Mukulika Baid, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Dr.Ambrish Mithal, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Amit Khosla, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Mr.Prakash Chand Surana, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Sandeep Bhargava, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Dr.Shailendra Raj Mehta, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Ms.Sonal Mattoo, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Naresh Vijayvergiya, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra, Mr.Avinash Chandra. Company has M C Bhandari & Co. as its auditors. As on 31-03-2024, the company has a total of 9.60 Crore shares outstanding.
Industry
Key Indices Listed On
Nifty 500, BSE 500, BSE 250 SmallCap Index, BSE SmallCap, BSE Healthcare
Address
No. 232-B, 3rd Floor,Okhla Industrial Estate,New Delhi, Delhi - 110020
Executive Leadership
Devendra Raj Mehta
ChairmanDevendra Raj Mehta
ChairmanDevendra Raj Mehta
ChairmanDevendra Raj Mehta
ChairmanAuditors
FAQs about Poly Medicure share
- 1. What's the Poly Medicure share price today?Poly Medicure share price was Rs 2,075.85 as on 05 Jul, 2024, 03:58 PM IST. Poly Medicure share price was up by 1.35% based on previous share price of Rs. 1957.25. In last 1 Month, Poly Medicure share price moved up by 16.89%.
- 2. What's the market capitalization of Poly Medicure?Within the Hospitals & Allied Services sector, Poly Medicure stock has a market cap rank of 7. Poly Medicure has a market cap of Rs 19,922.23 Cr.
- 3. Who is the chairman of Poly Medicure?Devendra Raj Mehta is the Chairman of Poly Medicure
- 4. What is the CAGR of Poly Medicure?The CAGR of Poly Medicure is 15.01.
- 5. What is Poly Medicure's 52 week high / low?52 Week high of Poly Medicure share is Rs 2,111.00 while 52 week low is Rs 1,075.00
- 6. Who's the owner of Poly Medicure?Following are the key changes to Poly Medicure shareholding:
- Promoter holding have gone down from 53.31 (30 Jun 2023) to 53.15 (31 Mar 2024)
- Domestic Institutional Investors holding has gone up from 4.25 (30 Jun 2023) to 7.21 (31 Mar 2024)
- Foreign Institutional Investors holding have gone down from 15.61 (30 Jun 2023) to 12.37 (31 Mar 2024)
- Other investor holding has gone up from 26.83 (30 Jun 2023) to 27.27 (31 Mar 2024)
- 7. Is Poly Medicure a good buy?As per Refinitiv (erstwhile Thomson Reuters), overall mean recommendation by 4 analysts for Poly Medicure stock is to Strong Buy. Recommendation breakup is as follows
- 2 analysts are recommending Strong Buy
- 2 analysts are recommending to Buy
- 8. Who are the peers for Poly Medicure in Hospitals & Allied Services sector?Nureca Ltd. is the key peer to compare Poly Medicure.
- 9. What are the key metrics to analyse Poly Medicure Share Price?Key Metrics for Poly Medicure are:
- PE Ratio of Poly Medicure is 77.14
- Price/Sales ratio of Poly Medicure is 11.08
- Price to Book ratio of Poly Medicure is 13.37
- 10. Is Poly Medicure giving dividend?Poly Medicure Ltd. announced an equity dividend of 60% on a face value of 5.0 amounting to Rs 3 per share on 09 May 2023. The ex dividend date was 21 Sep 2023.
- 11. What are the returns for Poly Medicure share?Return Performance of Poly Medicure Shares:
- 1 Week: Poly Medicure share price moved up by 7.53%
- 1 Month: Poly Medicure share price moved up by 16.89%
- 3 Month: Poly Medicure share price moved up by 32.43%
- 6 Month: Poly Medicure share price moved up by 39.60%
- 12. What are the Poly Medicure quarterly results?On Consoldiated basis, Poly Medicure reported a total income and profit of Rs 393.05 Cr and Rs 68.36 respectively for quarter ending 2024-03-31. Total Income and profit for the year ending 2024-03-31 was Rs 1434.54 Cr and Rs 258.26 Cr.
- 13. What is the PE & PB ratio of Poly Medicure?The PE ratio of Poly Medicure stands at 73.37, while the PB ratio is 12.89.
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.